Related Experiment Videos
Role of Staphylococcus aureus exfoliatin toxin in staphylococcal infections in mice
Chemotherapy
|January 1, 1981
Abstract:
Clindamycin at a concentration of 0.18 microgram/ml reduced growth of Staphylococcus aureus in vitro by 40% but inhibited exfoliatin toxin production by 90%. Mice infected with S. aureus and subsequently treated with clindamycin did not exfoliate but still died.
Insights
Clindamycin (0.18 microgram/ml) reduced Staphylococcus aureus growth by 40% and toxin production by 90% in vitro. While preventing exfoliation in mice, clindamycin treatment did not prevent mortality.
Area of Science:
- Microbiology
- Pharmacology
- Dermatology
Background:
- Staphylococcus aureus is a common pathogen.
- Exfoliatin toxin causes skin exfoliation.
- Clindamycin is an antibiotic used to treat S. aureus infections.
Purpose of the Study:
- To investigate the effect of clindamycin on Staphylococcus aureus growth and exfoliatin toxin production in vitro.
- To evaluate the efficacy of clindamycin in preventing skin exfoliation in a mouse model of S. aureus infection.
Main Methods:
- In vitro assays were used to determine the effect of clindamycin on S. aureus growth and exfoliatin toxin production.
- A mouse model was used to assess the in vivo efficacy of clindamycin in preventing skin exfoliation.
Main Results:
- Clindamycin at 0.18 microgram/ml reduced S. aureus growth by 40% and exfoliatin toxin production by 90% in vitro.
- Mice infected with S. aureus and treated with clindamycin did not exhibit skin exfoliation.
- Despite preventing exfoliation, clindamycin treatment did not reduce mortality in the infected mice.
Conclusions:
- Clindamycin effectively inhibits Staphylococcus aureus exfoliatin toxin production in vitro.
- Clindamycin may prevent skin exfoliation in S. aureus infections.
- Clindamycin alone may not be sufficient to prevent mortality in severe S. aureus infections.